Psilocybin.
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US Drug Enforcement Agency (DEA) reverses its decision to schedule five psychedelic substances under the most restrictive class of drugs
  • Advocates and researchers pled their case in a DEA hearing, highlighting the potential medical and research benefits of the drugs
  • Following this hearing, the DEA withdrew its move to schedule the drugs and cancelled any further hearings
  • The news is a big win for US researchers who would have faced the brunt of the drug restrictions as well as higher costs
  • The drugs will remain illegal when used recreationally but will allow researchers to uncover potential medical treatments

The US Drug Enforcement Agency (DEA) has reversed its decision to schedule five psychedelic substances under the most restrictive class of drugs.

This category is usually reserved for substances that have no medical use and a high potential for abuse.

In January, the DEA made the move to schedule the drugs under this category, causing considerable public backlash due to the potential medical benefits.

This included a letter from a group of members of Congress urging the DEA to allow terminally ill patients the right to access psilocybin.

Advocates and researchers pled their case in a DEA hearing, highlighting the potential medical and research benefits of the drugs, one of which showed the potential to treat postpartum depression and treatment-resistant depression.

Following this hearing, the DEA withdrew its move to schedule the drugs and cancelled any further hearings.

It reasoned more updated scientific and medical evaluations were required from the Department of Health and Human Services.

The news is a big win for US researchers who would have faced the brunt of the drug restrictions as well as higher costs.

Psychedelic start-ups have been gaining traction recently, with billions invested into the industry and increasing acceptance from the US Food and Drug Administration.

The drugs will remain illegal when used recreationally but will allow researchers to uncover potential medical treatments.

More From The Market Online
Michele Bullock speaks at an RBA press conference.

Knuckle down folks: The RBA clearly has a battle plan no nagging will shake

All through yesterday, there was one claim louder than the rest as Australia
AI image representing commodity price trends

Waning appetites for green metals and the ‘comfortable’ safe haven of gold: Thoughts on investment and commodities

Lithium's past highs and recent lows, in addition to copper's rally and gold's strong performance are…
Two miners digging in a cave awash with gold light.

The ASX gold miners benefiting most from gleaming bullion prices

Gleaming gold prices across the globe have helped several ASX gold miners sparkle especially bright as…
Image representing economic data.

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Australian GDP for the June quarter came in on-target at 0.2%, the same figure as in…